Unclassifiable interstitial lung disease: A review

Respirology

Volumn 21, Issue 1, 2016, Pages 51-56

  Skolnik, Kate ^a   Ryerson, Christopher J ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

diffuse lung disease; idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; interstitial lung disease; unclassifiable

Indexed keywords

AZATHIOPRINE; NINTEDANIB; PREDNISONE;

CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; PATHOLOGIST; PATIENT CARE; PRIORITY JOURNAL; RADIOLOGIST; REVIEW; UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE; CLASSIFICATION; LUNG DISEASES, INTERSTITIAL; NOMENCLATURE; PROGNOSIS;

HUMANS; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; TERMINOLOGY AS TOPIC;

EID: 84952872754     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12568     Document Type: Review

References (27)

1. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733-748.
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002; 165: 277-304.
3. Zhang D, Liu Y,. Surgical lung biopsies in 418 patients with suspected interstitial lung disease in China. Intern. Med. 2010; 49: 1097-1102.
4. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE Jr, Wolters PJ, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur. Respir. J. 2013; 42: 750-757.
5. Morell F, Reyes L, Domenech G, De Gracia J, Majo J, Ferrer J,. [Diagnoses and diagnostic procedures in 500 consecutive patients with clinical suspicion of interstitial lung disease]. Arch. Bronconeumol. 2008; 44: 185-191.
6. Xaubet A, Ancochea J, Morell F, Rodriguez-Arias JM, Villena V, Blanquer R, Montero C, Sueiro A, Disdier C, Vendrell M, et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc. Diffuse Lung Dis. 2004; 21: 64-70.
7. Hyldgaard C, Hilberg O, Muller A, Bendstrup E,. A cohort study of interstitial lung diseases in central Denmark. Respir. Med. 2014; 108: 793-799.
8. Troy L, Glaspole I, Goh N, Zappala C, Hopkins P, Wilsher M, Moodley Y, Corte T,. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur. Respir. J. 2014; 43: 1529-1530.
9. Pajares V, Puzo C, Castillo D, Lerma E, Montero MA, Ramos-Barbõn D, Amor-Carro O, Gil de Bernabé A, Franquet T, Plaza V, et al. Diagnostic yield of transbronchial cryobiopsy in interstitial lung disease: a randomized trial. Respirology 2014; 19: 900-906.
10. Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, Ryu JH, Carretta E, Tantalocco P, Piciucchi S, Ravaglia C, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS ONE 2014; 9: e86716.
11. Lee HY, Seo JB, Steele MP, Schwarz MI, Brown KK, Loyd JE, Talbert JL, Schwartz DA, Lynch DA,. High-resolution CT scan findings in familial interstitial pneumonia do not conform to those of idiopathic interstitial pneumonia. Chest 2012; 142: 1577-1583.
12. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF,. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549-554.
13. Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S, Nishimura K, Taniguchi H,. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008; 13: 394-399.
14. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, Cayou C, Shariat C, Collard HR,. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009; 135: 442-447.
15. Ryerson CJ, Cayou C, Topp F, Hilling L, Camp PG, Wilcox PG, Khalil N, Collard HR, Garvey C,. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir. Med. 2014; 108: 203-210.
16. Vainshelboim B, Oliveira J, Yehoshua L, Weiss I, Fox BD, Fruchter O, Kramer MR,. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration 2014; 88: 378-388.
17. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
18. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2013. [Accessed 13 Nov 2014.] Available from URL: http://www.goldcopd.org/
19. Idiopathic Pulmonary Fibrosis Clinical Research N, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G,. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2093-2101.
20. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071-2082.
21. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 2014; 145: 723-728.
22. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156: 684-691.
23. Cottin V, Wells A,. Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category? Eur. Respir. J. 2013; 42: 576-579.
24. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 (Suppl. 5): v1-58.
25. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am. J. Respir. Crit. Care Med. 2012; 185: 1004-1014.
26. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ,. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am. J. Respir. Crit. Care Med. 2011; 184: 842-847.
27. Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ,. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968-1977.